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Abstract
Angiosarcomas are malignant endothelial cell tumors with few effective systemic treatments. Despite a unique
endothelial origin, molecular candidates for targeted therapeutic intervention have been elusive. In this study, we
explored the tunica internal endothelial cell kinase 2 (Tie2) receptor as a potential therapeutic target in angiosarcoma.
Human angiosarcomas from diverse sites were shown to be universally immunoreactive for Tie2. Tie2 and vascular
endothelial growth factor receptor (VEGFR) antagonists inhibited SVR and MS1-VEGF angiosarcoma cell survival
in vitro. In the high-grade SVR cell line, Tie2 and VEGF antagonists inhibited cell survival synergistically, whereas
effects were largely additive in the low-grade MS1-VEGF cell line. Xenograft modeling using these cell lines closely
recapitulated the human disease. In vivo, Tie2 and VEGFR inhibition resulted in significant angiosarcoma growth
delay. The combination proved more effective than either agent alone. Tie2 inhibition seemed to elicit tumor growth
delay through increased tumor cell apoptosis, whereas VEGFR inhibition reduced tumor growth by lowering tumor
cell proliferation. These data identify Tie2 antagonism as a potential novel, targeted therapy for angiosarcomas
and provide a foundation for further investigation of Tie2 inhibition, alone and in combinations, in the management
of this disease.
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Introduction
Angiosarcoma is an uncommon, aggressive subtype of soft tissue sar-
coma composed of malignant endothelial cells. Current treatment strat-
egies are woefully inadequate. Despite aggressive therapy, only about
half of patients presenting with resectable tumors will be cured of their
disease. The median survival of patients presenting with unresectable
disease is less than 1 year [1].
Progress in developing novel therapeutic approaches to angiosarcoma
has been hindered by the rarity of this disease coupled with a dearth
of models to support preclinical investigations. However, two lines of
evidence highlight potential roles for antagonists of endothelial growth
factor signaling pathways. First, preclinical studies suggest that angio-
sarcomas share critical molecular features with normal endothelial
cells. Specifically, angiosarcomas have been shown to express vascular
endothelial growth factor A (VEGF-A) and multiple VEGF receptors
(VEGFRs), including the major proangiogenic VEGF-A receptor,
VEGFR2 [2–6]. Moreover, a murine endothelial cell line engineered
to overexpress VEGF-A forms invasive angiosarcomas in immuno-
deficient mice [7]. Evidence addressing the expression of other endo-
thelial growth factor signaling pathway components is scant. Brown
et al. [8] examined two cutaneous angiosarcomas and found that tunica
internal endothelial cell kinase 2 (Tie2) receptor messenger RNA was
Abbreviations: Ang, angiopoietin; Tie, tunica internal endothelial cell kinase (i.e., TEK);
VEGF, vascular endothelial growth factor; VEGFR, VEGF receptor
Address all correspondence to: Kevin R. Kozak, MD, PhD, Department of Human
Oncology, School of Medicine and Public Health, University of Wisconsin–Madison,
1111HighlandAve,WIMR3153,Madison,WI 53705. E-mail: kozak@humonc.wisc.edu
1This was supported in part by a National Institutes of Health grant (1UL1RR25011).
The authors have no conflicting commercial or financial interests.
2This article refers to supplementary materials, which are designated by Figures W1 and
W2 and are available online at www.neoplasia.com.
Received 18 December 2011; Revised 25 January 2012; Accepted 26 January 2012
Copyright © 2012 Neoplasia Press, Inc. All rights reserved 1522-8002/12/$25.00
DOI 10.1593/neo.111770
www.neoplasia.com
Volume 14 Number 2 February 2012 pp. 131–140 131
strongly expressed in both lesions. The Tie2 receptor ligands, angio-
poietin 1 (Ang1) and Ang2, were also expressed in both angiosarcoma
specimens. Stacher et al. [9] observedTie2 expression in 7 of 10 examined
pulmonary epithelioid angiosarcomas.
The second line of evidence supporting a potential role for anti-
angiogenic/antiendothelial therapies in angiosarcoma derives from
early clinical experience with VEGF antagonists. Clinical responses
have been reported with bevacizumab, a monoclonal antibody di-
rected at VEGF-A, in cutaneous angiosarcomas of the face [10–12].
Interim results of a multicenter phase 2 study of bevacizumab in un-
resectable angiosarcoma and epithelioid hemangioendothelioma pa-
tients showed a 15% partial response rate with disease stabilization in
63% of patients [13]. Results with VEGFR tyrosine kinase inhibitors in
unselected soft tissue sarcoma patients, including sorafenib, pazopanib,
and sunitinib, are more challenging to interpret because of the small
number of angiosarcoma patients in these trials; however, clinical
activity has been observed with sorafenib [14–17].
The Ang-Tie2 system plays critical roles in endothelial cell sur-
vival and proliferation, vascular plasticity, and angiogenesis [18]. Con-
sequently, there is considerable interest in modulators of the Ang-Tie2
axis as antiangiogenic agents for treatment of solid tumors and several
candidate drugs have emerged. Results of the first phase 1 study of an
Ang-Tie2 axis-targeted therapy in patients with advanced solid tumors
have recently been reported and documented good tolerance and prom-
ising antitumor activity [19].
On the basis of a promising molecular rationale, and the growing
availability of pharmacophores, we hypothesized that Tie2 inhibition
may have therapeutic utility in angiosarcoma. To test this hypothesis,
we examined the expression of Tie2 in a panel of human angiosarcomas
from diverse sites. We then evaluated a selective Tie2 receptor tyrosine
kinase inhibitor, with and without the clinically used VEGFR tyrosine
kinase inhibitor sunitinib, in vitro and in vivo using two mouse models
of angiosarcoma.
Materials and Methods
Cell Lines and Pharmacologic Agents
SVR and MS1-VEGF cells were obtained from the American Type
Culture Collection (Manassas, VA). Cells were cultured in Dulbecco
modified Eagle medium containing 5% fetal bovine serum and 1%
penicillin/streptomycin. Human umbilical vein endothelial cells were
obtained from Lonza (Basel, Switzerland) and cultured in endothelial
growth medium 2. Sunitinib was obtained from Cayman Chemical
(Ann Arbor, MI), and purity was confirmed by thin-layer chromatogra-
phy. The selective Tie2 kinase inhibitor 4-(6-methoxy-2-naphthyl)-2-
(4-methylsulfinylphenyl)-5-(4-pyridyl)-1H -imidazole was obtained
from EMD4Biosciences (Darmstadt, Germany) and Selleck Chemicals
(Houston, TX). 1H nuclear magnetic resonance (DMSO-d6) con-
firmed structure [20]. Purity was shown to be greater than 96% by
high-performance liquid chromatography.
Immunoblot Analysis
HUVEC, SVR, and MS1-VEGF cells were grown to approximately
70% confluence. Cells were washed twice in cold PBS and protein iso-
lated in cold NP-40 lysis buffer (50 mM HEPES (pH 7.4), 150 mM
NaCl, 1% NP-40, 0.5% deoxycholic acid, 10% glycerol, 2.5 mM
EGTA, 1 mM EDTA, 1 mM dithiothreitol, 1 mM phenylmethane-
sulfonyl fluoride, 1 mM Na3VO4, 20 mM beta-glycerophosphate,
10 μg/ml of leupeptin and aprotinin). Proteins were quantified using
a standard Bradford absorbance assay. Proteins were separated on 4% to
20% gradient SDS-PAGE gels and transferred to polyvinylidene fluo-
ride membrane by electrophoretic transfer. Membranes were subse-
quently blocked in 5% nonfat milk or bovine serum albumin in
1 mM Tris, pH 8.0, 150 mM NaCl, 0.5% Tween 20. Primary anti-
bodies for Western blot detection of VEGFR2 (1:1000; Santa Cruz
Biotechnology, Inc, Santa Cruz, CA) or Tie2 (1:1000; Santa Cruz Bio-
technology, Inc) were applied overnight at 4°C. Secondary antibody
for detection was either goat antirabbit immunoglobulin G (IgG)
HRP (Tie2, 1:4000; Santa Cruz Biotechnology, Inc) or goat antimouse
IgG-HRP (VEGFR-2, 1:4000; Santa Cruz Biotechnology, Inc). Pro-
teins were detected through enhanced chemiluminescence detection
system (Amersham Biosciences, Buckinghamshire, United Kingdom).
Cell Survival Assays
SVR and MS1-VEGF cells were plated at 1500 cells per well in
96-well plates and allowed to adhere overnight. The medium was aspi-
rated and replaced with fresh medium containing varying concentra-
tions of sunitinib, Tie2 kinase inhibitor, or DMSO vehicle control.
The final concentration of DMSO was 0.1%. Cells were allowed to
grow for 72 hours, and cell survival was quantified using the WST-1
cell proliferation reagent (Clontech Laboratories, Mountain View, CA)
according to the manufacturer’s instructions. Cell survival assays ex-
amining combined treatment were similarly performed at a fixed Tie2
kinase inhibitor-to-sunitinib molar ratio of 25:1 (to reflect relative drug
potencies) at total drug concentrations of 26 to 7800 nM. Combina-
tion index analyses were conducted using CompuSyn (ComboSyn,
Inc, Paramus, NJ).
In Vivo Studies
Athymic nude mice (6- to 8-week-old females) were obtained from
Harlan Laboratories, Inc (Indianapolis, IN). The care and treatment
of experimental animals were in accordance with institutional guide-
lines. SVR and MS1-VEGF cells (2 × 106 cells) were implanted sub-
cutaneously. For histopathologic confirmation of the angiosarcoma
phenotype, SVR tumors were excised at days 3, 6, 9, and 12 after
injection, and MS1-VEGF tumors were excised at days 5, 10, 15,
and 20 after injection. For tumor growth delay studies, treatment
was started when the tumor volume reached 200 mm3 (SVR) or when
palpable (MS1-VEGF). Animals were randomized into four treatment
groups. The control group and the Tie2 kinase inhibitor alone group
were treated daily with 100 μl of vehicle (0.5% carboxymethylcellulose,
0.4% Tween 80, 1.8% NaCl, and 0.9% benzyl alcohol in distilled
water, pH 6.0) by oral gavage. The sunitinib-alone and combination
treatment groups were treated daily with 100 μl of vehicle contain-
ing sunitinib (60 mg/kg for SVR tumors, 30 mg/kg for MS1-VEGF
tumors) by oral gavage. The control and sunitinib-alone groups were
treated twice weekly with 100 μl of vehicle (5% ethanol, 5%Cremophor,
and 90% distilled water) through intraperitoneal injection. The Tie2
kinase inhibitor–alone and combination treatment groups were in-
jected twice weekly with 100 μl of vehicle containing Tie2 kinase in-
hibitor (50 mg/kg). Tumor volume was determined by direct caliper
measurement and calculated by the following formula: volume =
0.5 × (large diameter) × (small diameter)2. For necrosis, apoptosis,
and proliferation studies in vivo, SVR tumor-bearing animals (n = 4-6
per group) were randomized and treated as above for 11 days. On
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day 12, animals were killed, and tumors were harvested for histologic and
immunohistochemical analyses. Percent tumor necrosis was estimated by
a pathologist (D.B.) blinded to treatment using hematoxylin and eosin–
stained whole tumor sections. The number of cleaved caspase 3 and
PCNA-positive cells per high-power field (n = 5/tumor) was quantified
by an observer blinded to treatment.
Immunohistochemical Analyses
Formalin-fixed, paraffin-embedded angiosarcoma specimens were
obtained from the University of Wisconsin’s surgical pathology ar-
chives on an institutional review board–approved protocol, and
the diagnosis was confirmed by a pathologist with expertise in soft
tissue sarcomas.
For Tie2, tissue sections (5 μm thick) were cut using traditional
water bath technique and dried overnight at room temperature. Slides
were deparaffinized in subsequent xylene and ethanol incubations,
followed by heat-induced epitope retrieval using the Lab Vision PT
module (Thermo Fisher Scientific, Fremont, CA) with Lab Vision
citrate buffer pH 6.0 at 98°C for 20minutes without boiling. Immuno-
labeling was performed at room temperature using the Lab Vision 360
automated staining system following a standard biotin-avidin protocol.
Biocare Medical (Concord, CA) were used except where noted. Endog-
enous peroxidase was blocked for 5 minutes with Peroxidazed 1. Non-
specific protein binding was eliminated through a 30-minute block
with Sniper, and nonspecific avidin was blocked using the Avidin
Biotin kit, with a 15-minute incubation for each reagent. Slides were
incubated with 1:50 dilution of goat anti-Tie2 IgG (R&D Systems,
Minneapolis, MN) for 60 minutes followed by incubation with bioti-
nylated swine antigoat IgG 1:50 (Invitrogen, Carlsbad, CA) and 4plus
Streptavidin-HRP treatment. Betazoid DAB and Mayer hematoxylin
Figure 1. Specificity of Tie2 immunostaining and Tie2 expression in human angiosarcomas. Immunohistochemical evaluation of Tie2
expression was performed as described in Materials and Methods (magnification, ×400). (A) Ischemic fasciitis (positive control) showing
the expected expression of Tie2 in endothelial cells. (B) Uniform expression of Tie2 was observed in a primary small bowel angiosarcoma.
(C) Primary small bowel angiosarcoma processed without secondary antibody (negative control). (D-M) Hematoxylin and eosin and Tie2
immunohistochemical evaluation of 10 additional representative human angiosarcomas: extremity soft tissue (D), bone (E), bladder (F), scalp
(G), peristernal soft tissue (H), liver (I), small intestine (J), periumbilical soft tissue (K), chest wall (after radiation) (L), and spleen (M).
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were each incubated for 1 minute. All antibodies were diluted using
Renaissance Background Reducing Diluent. Slides were washed with
Tris-buffered saline–Tween after each reagent. Tie2 immunoreactivity
was scored by two authors (K.R.K. and D.B.): 0 indicates negative; 1+,
weak; 2+, moderate; and 3+, strong staining.
For PCNA and cleaved caspase 3 immunohistochemistry, tissue was
fixed for 24 hours in 10% neutral buffered formalin, dehydrated
through graded ethyl alcohols, paraffin infiltrated, and embedded.
Tissue sections were cut at 5 μm and mounted on slides. Slides were
deparaffinized in xylene and hydrated through graded ethyl alcohols
to water. Slides were washed with PBS three times. Nonspecific bind-
ing was blocked with 10% goat serum in PBS for 1 hour, and endoge-
nous peroxidase was blocked with 0.3% hydrogen peroxide in PBS for
10 minutes. Endogenous biotin was blocked with 0.001% avidin in
PBS for 10 minutes, and avidin was quenched with 0.001% biotin
in PBS for 10 minutes. The slides were then incubated with either
anti-PCNA (Novus, Littleton, CO) at a 1:200 dilution in PBS with
1% goat serum and 0.001% Triton X-100 or anti–cleaved caspase 3
(Asp175) (Cell Signaling Technology, Inc, Danvers, MA) at a 1:800
dilution in PBS with 1% goat serum overnight at 4°C. After washing
with PBS, the sections were incubated with biotinylated goat anti-rabbit
IgG (Vector Laboratories, Burlingame, CA) at 1:200 in PBS for one hour
at room temperature. Slides were washed in PBS and then incubated
30minutes at room temperature with Vectastain ABC Elite (Vector Lab-
oratories). After PBS wash, slides were developed with DAB (Vector
Laboratories), counterstained with Mayer hematoxylin. All reagents
and chemicals were from Sigma (St Louis, MO), unless otherwise noted.
Statistical Analyses
Data are presented as means ± SE. Multigroup comparisons were
conducted by analysis of variance (GraphPad Prism;GraphPad Software,
La Jolla, CA) with Bonferroni posttest corrections for multiple compar-
isons unless otherwise specified.
Results
To assess Tie2 expression in a diverse set of human angiosarcomas, we
first confirmed the specificity of Tie2 immunohistochemistry in normal
intestinal wall and in ischemic fasciitis. As expected, Tie2 immuno-
reactivity was identified in the vascular endothelium (Figure 1A). We
then tested Tie2 immunoreactivity in a case of human angiosarcoma
(small bowel primary) and found uniform, moderate Tie2 expression
in malignant cells (Figure 1B). Ten additional specimens from diverse
primary sites were then examined. As shown in Figure 1D toM , strong
Tie2 expression was identified in 50%, moderate expression in 40%,
and weak expression in 10% of the specimens. These results raise
the possibility that the Tie2 receptor may represent a therapeutic target
in angiosarcoma.
To test the hypothesis that Tie2 receptor antagonism may have
therapeutic potential in angiosarcoma, models that recapitulate the
human disease are required. Arbiser et al. [7,21] have reported the gen-
eration of two cell lines that form angiosarcomas in mice. Using an
immortalized, murine endothelial cell line (MS1), they showed that
introduction of activated H-ras yields a cell line (SVR) that forms
rapidly growing angiosarcomas in vivo. Similarly, overexpression of
primate VEGF 121 in the parental MS1 cell line results in a cell line
(MS1-VEGF) capable of forming slow-growing angiosarcomas in mice.
To confirm the utility of these models for assessing vascular targeted
therapies in angiosarcoma, we first examined the expression of Tie2
and VEGFR2 in these cells. As shown in Figure 2, both SVR and
MS1-VEGF cells express Tie2 and VEGFR2.On the basis of its clinical
availability, promise in this disease setting and lack of activity against
the Tie2 receptor, the VEGFR inhibitor, sunitinib, was selected as a
model VEGFR antagonist [22]. Tie2 antagonists have not yet reached
the clinic. However, Semones et al. [20], using a combination of library
screening and in silico design, developed a highly selective Tie2 kinase
inhibitor, 4-(6-methoxy-2-naphthyl)-2-(4-methylsulfinylphenyl)-5-(4-
pyridyl)-1H-imidazole (Tie2 kinase inhibitor) with in vivo activity in
mouse. This inhibitor was used as the model Tie2 antagonist in vitro
and in vivo.
The effects of VEGFR and Tie2 antagonism on cell survival were
then assessed in vitro. As shown in Figure 3, both sunitinib and Tie2
kinase inhibitor modestly reduced SVR and MS1-VEGF cell survival
in a dose-dependent manner. Unsurprisingly, MS1-VEGF cells were
more sensitive to sunitinib than SVR cells were. In contrast, SVR cells
were modestly more sensitive to Tie2 kinase inhibition than MS1-
VEGF cells were. To test for potential cytotoxic synergy of dual Tie2
and VEGFR inhibition, SVR and MS1-VEGF cells were treated with
the combination of sunitinib and Tie2 kinase inhibitor, and a com-
bination index analysis was conducted. The combined treatment was
synergistic against SVR cells throughout the fractional affect range,
whereas the combination was generally additive in MS1-VEGF cells
(Figure 3C).
To confirm the angiosarcomagenic potential of SVR and MS1-
VEGF cells, time course experiments were performed to examine the
temporal evolution of gross and microscopic tumor phenotype. Sub-
cutaneous implantation of SVR cells into athymic nude mice resulted
in rapidly progressive, purpuric nodules reminiscent of the human
disease (Figure 4A). Implantation of MS1-VEGF cells resulted in
Figure 2. Expression of VEGFR2 and Tie2 in SVR and MS1-VEGF
cells. SVR and MS1-VEGF cells express both the Tie2 and VEGFR2
receptors; human umbilical vein endothelial cells are shown as a
positive control.
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slow-growing, faintly violaceous nodules (Figure 4B). Histomorphologi-
cally, both SVR and MS1-VEGF lesions very closely resemble human
angiosarcoma. As seen in Figure 4C to D, both early SVR tumors and
MS1-VEGF tumors display the irregular, anastomosing vascular chan-
nels characteristic of angiosarcoma. Lesional cells are epithelioid or spin-
dledwith significant nuclear pleiomorphism, high nuclear-to-cytoplasmic
ratios, and hyperchromatic nuclei. The malignant, infiltrating character
of the lesions is best observed in day 12 SVR tumors where frank skeletal
muscle invasion is evident. Both tumors retained expression of Tie2 as
well as diagnostic expression of CD31 (Figures W1 and W2).
The sensitivity of SVR and MS1-VEGF angiosarcomas to VEGFR
and Tie2 kinase inhibition was then tested in vivo. In SVR tumors
(Figure 5A), sunitinib (60 mg/kg, orally everyday), Tie2 kinase in-
hibitor (50 mg/kg, intraperitoneally, twice a week), and the combina-
tion resulted in statistically significant reductions in tumor volume
by day 15. By day 20, sunitinib treatment resulted in a 44% reduction
in tumor volume compared with control-treated animals (P < .01).
Tie2 kinase inhibitor treatment resulted in a 61% reduction in tumor
volume (P < .01). The combination of sunitinib and Tie2 kinase in-
hibitor resulted in the greatest tumor volume reduction (70%; P <
.01). The combination was more potent than sunitinib alone (P <
.01) and Tie2 kinase inhibitor alone, although the latter did not reach
statistical significance after correction for multiple comparisons (P >
.05). No differences in animal weights were observed between groups
at any time point (P > .3).
Mice bearing MS1-VEGF tumors were similarly treated with sunitinib
(30 mg/kg, orally everyday), Tie2 kinase inhibitor (50 mg/kg, intra-
peritoneally, twice a week), or the combination (Figure 5B). Persis-
tent, statistically significant tumor growth delay was observed for all
treatment groups by day 33. Compared with control-treated mice,
sunitinib treatment reduced tumor volume by 41% (P < .01) and Tie2
kinase inhibitor treatment reduced tumor volume by 45% (P < .01) by
6 weeks. Combined treatment resulted in the greatest tumor volume
reduction (74% vs control, P < .01). As in the case of SVR tumors, com-
bined treatment displayed greater activity than monotherapy with either
sunitinib or Tie2 kinase inhibitor, and these differences reached statistical
significance by 6 weeks (P < .05). No differences in animal weights were
observed between groups at any time point (P > .15).
To identify potential mechanisms of tumor growth delay, SVR tumor-
bearing mice (n = 4-6 per group) were treated as above for 11 days and
killed at day 12 for tumor histologic and immunohistochemical analy-
sis. Tumors from control-treated animals displayed 27% ± 7% necrosis.
Sunitinib treatment, Tie2 kinase inhibitor treatment and combination treat-
ment resulted in 48% ± 9% (P = .1 vs control, Student’s t test), 41% ± 8%
(P = .2, Student’s t test) and 39 ± 8% (P = .3, Student’s t test) necrosis.
Apoptosis was assessed by cleaved caspase 3 immunohistochemistry
(Figure 6A). Consistent with its activity in vivo, Tie2 kinase inhibitor treat-
ment led to a three-fold increase in cleaved caspase 3–positive cells com-
pared with tumors from control-treated animals (P < .05). Sunitinib
had no significant effect on the number of cleaved caspase 3–positive
Figure 3. Inhibition of SVR (solid line) and MS1-VEGF (dashed line) cell survival by sunitinib (A) and Tie2 kinase inhibitor (B) and dose
effect analysis of combined sunitinib and Tie2 kinase inhibitor (C). Cell survival was determined as described in Materials and Methods.
Combination indices <1, =1, and >1 denote synergy, additivity, and antagonism, respectively. Values represent mean ± SE (n = 4).
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cells compared with control-treated animals (P > .05) and the combi-
nation of sunitinib and Tie2 kinase inhibitor yielded intermediate levels
of apoptosis (P < .05). In contrast, sunitinib markedly reduced the
number of proliferating (PCNA-positive) tumor cells compared with
control-treated animals (Figure 6B), although this did not achieve sta-
tistical significance after correction for multiple comparisons (P > .05).
Unexpectedly, Tie2 kinase inhibitor treatment, alone or in combina-
tion with sunitinib, led to a dramatic increase in PCNA-positive tumor
cells compared with both control- and sunitinib-treated animals (P <
.05 for each comparison).
Discussion
This study presents evidence supporting a role for Tie2 targeting in the
treatment of angiosarcoma. After confirming the specificity of Tie2
immunostaining, we demonstrated expression of this vascular tyrosine
kinase receptor in a panel of human angiosarcomas from diverse sites
(Figure 1). This finding extends the observations of Brown et al. [8]
who found strong Tie2 messenger RNA expression in two human
angiosarcomas and is largely consistent with the findings of Stacher
et al. [9] who identified Tie2 expression in most pulmonary epithelioid
angiosarcomas. Intriguingly, the intensity of Tie2 immunoreactivity
Figure 4. SVR (A, C) andMS1-VEGF (B, D) tumor xenografts recapitulate the gross and microscopic phenotype of angiosarcoma. Represen-
tative gross appearance of SVR (A) andMSI-VEGF (B) tumors at the indicated day after implantation in mice. Note the bruise-like appearance
consistent with human cutaneous angiosarcomas. Representative histologic (hematoxylin and eosin) appearance of SVR (C) and MSI-VEGF
(D) tumors at the indicated day after implantation in mice. Note the hypercellularity and irregular vascular channels consistent with angio-
sarcoma. Skeletal muscle invasion is seen most prominently in day 12 SVR tumors.
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varied considerably among the 11 human angiosarcomas examined. This
observation raises the possibility that Tie2 expression, defined immuno-
histochemically, might serve as a predictive biomarker for Tie2-directed
therapies and warrants further exploration.
To facilitate testing the hypotheses that VEGFR and Tie2 ki-
nase inhibitors have activity in angiosarcoma, models of both well-
differentiated, slow-growing (MS1-VEGF), and poorly differentiated,
rapidly progressive (SVR) angiosarcomas were used. In line with prior
observations, VEGFR2 was expressed in both cell lines [7,21]. Consis-
tent with our immunohistochemical observations in human angio-
sarcomas, both cell lines also retained Tie2 expression (Figures 2 and
W1). Trials of VEGFR-directed therapies provide hints of clinical ac-
tivity in angiosarcoma [10–13,15–17], and SVR xenografts have been
used to screen for novel anti-VEGFR compounds [23–27]. However,
few data are available on the ability of VEGFR antagonists to directly
inhibit SVR tumor cell survival in vitro. Moreover, the activity of clini-
cally available VEGFR antagonists (e.g., sunitinib, sorafenib, pazopanib)
against SVR cells is largely undefined. Similarly, the cytotoxic potential
of Tie2 antagonists in the SVR cell line, or the related MS1-VEGF
cell line, is undefined. In this study, we found that both sunitinib and
the selective Tie2 kinase inhibitor, 4-(6-methoxy-2-naphthyl)-2-(4-
methylsulfinylphenyl)-5-(4-pyridyl)-1H-imidazole, reduced cell survival
in both SVR and MS1-VEGF cell lines in vitro (Figure 3).
Concurrent inhibition of the VEGF-VEGFR and Ang-Tie2 axes
in solid tumor antiangiogenic therapy has been explored based on
the hypothesis that such dual inhibition may more effectively ablate
tumor-driven angiogenesis compared with monotherapy [23,28]. To
assess potential antineoplastic synergy between VEGFR and Tie2
kinase inhibition in SVR and MS1-VEGF cells, formal combination
index analyses were performed. Intriguingly, dual inhibition proved po-
tently synergistic in the rapidly proliferating SVR cell line and largely
additive in the slowly proliferating MS1-VEGF line (Figure 3C ). In
addition to demonstrating the mechanistic independence of sunitinib
and the Tie2 kinase inhibitor, these data raise the possibility that dual
inhibition of VEGFR and Tie2 may be uniquely efficacious in poorly
differentiated angiosarcoma. Because poorly differentiated variants are
the most common angiosarcoma histology observed clinically, this
hypothesis merits further investigation.
After validation of SVR andMS1-VEGF cell models of angiosarcoma
in vivo (Figure 4), cell culture results were extended to mouse models of
the disease. In both tumors, sunitinib and Tie2 kinase inhibitor displayed
significant tumor growth delay. Combined therapy was more potent
Figure 5. In vivo SVR (A) and MS1-VEGF (B) tumor growth inhibition with sunitinib, Tie2 kinase inhibitor, and combination. Tumor-bearing
mice were treated as described in Materials and Methods (SVR n = 5, MS1-VEGF n = 4). *P < 0.05, control versus each treatment group.
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than monotherapy in both models. It is interesting to note that treat-
ment, either monotherapy or combined therapy, did not result in durable
tumor control. This observation is consistent with early clinical results
with VEGFR-directed therapies in angiosarcoma patients. Clinical bene-
fit is almost exclusively due to disease stabilization; confirmed responses
(i.e., reductions in tumor size) are uncommon. For example, in combined
analysis of phase 2 studies of sorafenib in this setting, only 5 of 45 vascular
sarcoma patients had confirmed responses as their best response. In con-
trast, stable disease was observed in 26 patients [15,16]. The consistency
between our preclinical findings and early clinical observations lend
support for the use of SVR and MS1-VEGF angiosarcoma models in
assessing the therapeutic utility of vascular-targeted agents in this disease.
Potentially more importantly, our observation that VEGFR and Tie2 ki-
nase inhibition results in angiosarcoma growth delay rather than tumor
regression suggests that such therapies may best be used in combination
with other agents.
Straightforward mechanistic studies were performed to identify poten-
tial mechanisms of tumor growth delay with VEGFR and Tie2 kinase
inhibition. As expected given the pro-proliferative effects of VEGF on
endothelial cells, sunitinib tended to increase tumoral necrosis and
reduce tumor cell proliferation in SVR tumors (Figure 6). Because
sunitinib did not modify tumor cell apoptosis in vivo, tumor delays seem
to be a simple function of reduced proliferation. This finding likely
explains why sunitinib monotherapy results in tumor growth delay
rather than tumor regression/cure. In stark contrast, Tie2 kinase inhibi-
tion and the drug combination paradoxically resulted in increased tumor
cell proliferation. Tumor growth delay seems to be achieved through
increased tumor cell apoptosis that more than offsets the observed
Figure 6. Apoptosis (A) and proliferation (B) of SVR cells in vivo in response to vehicle, sunitinib, Tie2 kinase inhibitor, and combination
treatment. Quantification of apoptotic (cleaved caspase 3 positive) and proliferating (PCNA positive) cells was as described in Materials
and Methods. n = 4-6 per group; values represent mean ± SE.
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increase in proliferation. Tie2 signaling has been implicated in both
endothelial cell proliferation and endothelial cell survival [29,30]. Several
hypotheses can be offered to explain the observed increases in both
apoptosis and proliferation in SVR tumors after Tie2 kinase (and dual)
inhibition. Because a single, low-dose regimen of Tie2 kinase inhibition
was examined in vivo, the relative effects of treatment on apoptosis and
proliferation may vary with dose intensity. Similarly, there may be tem-
poral changes in the balance between apoptosis and proliferation not
captured by the time point examined in this study. Increased tumor cell
proliferation after Tie2 kinase inhibition may simply reflect accelerated
repopulation similar to that observed in solid tumors treated with potent
cytotoxins (e.g., ionizing radiation). Finally, the apparent failure of Tie2
kinase inhibition to reduce tumor cell proliferation may also be a con-
sequence of the model used. Tie2-mediated increases in nonresting
endothelial cell proliferation are, at least in part, mediated by activation
of the Ras/Raf/MAPK pathway [29–31]. As SVR cells contain activated
H-ras, constitutive activation of this pathway may limit the impact of
Tie2 signaling disruption on cell proliferation. Defining the relative con-
tribution of various Tie2 functions on angiosarcoma development and
progression will be critical to the refined clinical application of Tie2
kinase inhibitors in this disease.
As discussed above, findings from these experiments as well as early
clinical experience with VEGF antagonists suggest that VEGFR- or
Tie2-directed therapies, alone or together, will be insufficient to achieve
durable tumor control. Consequently, the rational combination of these
therapies with other treatments active in angiosarcoma may offer the
best chance for genuine clinical progress. Few nonsurgical therapies
with well-evidenced activity in angiosarcoma are available and include
ionizing radiation and paclitaxel [32–34]. Both of these cytotoxic modal-
ities are dependent on cell proliferation for efficacy. Our results sug-
gest that concurrent use of either paclitaxel or ionizing radiation with
sunitinib may be suboptimal because the latter reduces tumor cell pro-
liferation rate and thus may blunt the efficacy of cytotoxic therapy. In
contrast, the observation that Tie2 kinase inhibition dramatically in-
creases tumor cell proliferation suggests this treatment may complement
cytotoxic therapies exceedingly well. Further investigation is needed to
define the potential roles for Tie2 kinase inhibitors in multimodality
angiosarcoma regimens.
Taken together, the results of this study highlight a potential role for
Tie2 kinase inhibition in angiosarcoma treatment. The Tie2 receptor is
expressed in human angiosarcomas. In two models of angiosarcoma,
Tie2 kinase inhibition reduced cell survival in vitro and delayed tumor
growth in vivo. Mechanistically, in vivo tumor growth delay seems to
be mediated by an increase in lesional cell apoptosis. Given the dearth
of effective therapies for this disease and its poor prognosis, further
preclinical and clinical investigations of Tie2 kinase inhibition are
warranted. More generally, the experimental approach used here may
prove valuable in the identification and testing of other potential
molecular targets in angiosarcoma.
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Figure W1. Tie2 expression in day 12 SVR (A) and day 20 MS1-VEGF (B) tumors. (C and D) The same tumors processed without primary
antibody (negative control).
Figure W2. CD31 expression in day 12 SVR (A) and day 20 MS1-VEGF (B) tumors. (C and D) The same tumors processed without primary
antibody (negative control).
